The influence of time horizon on results of cost-effectiveness analyses

被引:56
|
作者
Kim, David D. [1 ]
Wilkinson, Colby L. [1 ]
Pope, Elle F. [1 ]
Chambers, James D. [1 ]
Cohen, Joshua T. [1 ]
Neumann, Peter J. [1 ]
机构
[1] Tufts Med Ctr, Ctr Evaluat Value & Risk Hlth, Inst Clin Res & Hlth Policy Studies, 800 Washington St Box 63, Boston, MA 02111 USA
关键词
Time horizon; cost-effectiveness analysis; systematic review; health technology assessment; value assessment; PROSTATE-CANCER; FRAMEWORK; THERAPY;
D O I
10.1080/14737167.2017.1331432
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Debates persist on the appropriate time horizon from a payer's perspective and how the time horizon in cost-effectiveness analysis (CEA) influences the value assessment.Methods: We systematically reviewed the Tufts Medical Center CEA Registry and identifiedUS-based studies that used a payer perspective from 2005-2014. We classified the identified CEAs as short-term (time horizon 5years) and long-term (> 5years), and examined associations between study characteristics and the specified time horizon. We also developed case studies with selected interventions to further explore the relationship between time horizon and projected costs, benefits, and incremental cost-effectiveness ratios (ICER).Results: Among 782 identified studies that met our inclusion criteria, 552 studies (71%) utilized a long-term time horizon while 198 studies (25%) used a short-term horizon. Among studies that employed multiple time horizons, the extension of the time horizon yielded more favorable ICERs in 19 cases and less favorable ICERs in 4 cases. Case studies showed the use of a longer time horizon also yielded more favorable ICERs.Conclusion: The assumed time horizon in CEAs can substantially influence the value assessment of medical interventions. To capture all consequences, we encourage the use of time horizons that extend sufficiently into the future.
引用
收藏
页码:615 / 623
页数:9
相关论文
共 50 条
  • [41] Cost-effectiveness analyses of statistically ineffective treatments
    Trippoli, S
    Messori, A
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (23): : 1992 - 1992
  • [42] Future drug prices and cost-effectiveness analyses
    Hoyle, Martin
    [J]. PHARMACOECONOMICS, 2008, 26 (07) : 589 - 602
  • [43] STANDARDS FOR COST-EFFECTIVENESS ANALYSES IN THE CONTEXT OF DISSEMINATION
    Riley, William
    [J]. ANNALS OF BEHAVIORAL MEDICINE, 2018, 52 : S431 - S431
  • [44] Future Drug Prices and Cost-Effectiveness Analyses
    Martin Hoyle
    [J]. PharmacoEconomics, 2008, 26 : 589 - 602
  • [45] Cost-effectiveness analyses of preimplantation genetic testing
    Nadgauda, Ashni
    Ganti, Tej
    Walter, Jessica R.
    [J]. FERTILITY AND STERILITY, 2022, 121 (04) : 693 - 702
  • [46] Reporting cost-effectiveness analyses with confidence - Reply
    Siegel, JE
    Weinstein, MC
    Fryback, DG
    Manning, WG
    Torrance, GW
    Russell, LB
    Gold, MR
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (05): : 375 - 375
  • [47] Cost-effectiveness analyses of total ankle arthroplasty
    SooHoo, NF
    Kominski, G
    [J]. JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2004, 86A (11): : 2446 - 2455
  • [48] Clarifying Assumptions and Outcomes in Cost-effectiveness Analyses
    ten Haaf, Kevin
    de Koning, Harry J.
    [J]. JAMA ONCOLOGY, 2016, 2 (02) : 277 - 278
  • [49] A glimpse into the black box of cost-effectiveness analyses
    John-Baptiste, Ava A.
    Bell, Chaim
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2011, 183 (06) : E307 - E308
  • [50] Nonparametric statistical methods for cost-effectiveness analyses
    Dinh, Phillip
    Zhou, Xiao-Hua
    [J]. BIOMETRICS, 2006, 62 (02) : 576 - 588